60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has a cash flow conversion efficiency ratio of -0.501x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.69 Million) by net assets ($3.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 60 Degrees Pharmaceuticals, Inc. Common (SXTP) defensive interval to measure how many days the company can operate on defensive assets alone.
60 Degrees Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
60 Degrees Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 60 Degrees Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ocean Wilsons Holdings Ltd
LSE:OCN
|
0.030x |
|
Aptose Biosciences Inc
TO:APS
|
0.381x |
|
Pure Foods Tasmania Ltd
AU:PFT
|
-0.073x |
|
Spartoo SAS
PA:ALSPT
|
0.090x |
|
Veganz Group AG
F:VEZ
|
-0.582x |
|
Soligenix Inc.
NASDAQ:SNGX
|
-0.386x |
|
PBG SA
WAR:PBG
|
0.000x |
|
Forbidden Foods Ltd
AU:FFF
|
-0.112x |
Annual Cash Flow Conversion Efficiency for 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see how much is 60 Degrees Pharmaceuticals, Inc. Common worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.38 Million | $-6.85 Million | -2.027x | -41.92% |
| 2024-12-31 | $3.96 Million | $-5.65 Million | -1.428x | -50.83% |
| 2023-12-31 | $4.80 Million | $-4.54 Million | -0.947x | -2363.88% |
| 2022-12-31 | $-24.15 Million | $-1.01 Million | 0.042x | +16.97% |
| 2021-12-31 | $-18.15 Million | $-649.11K | 0.036x | +286.20% |
| 2020-12-31 | $-18.07 Million | $-167.30K | 0.009x | -- |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more